collaboration

Bioinformatics firm M2Gen will analyze whole-exome sequencing and tumor RNA-seq data for the HudsonAlpha genomic lab affiliate.

Avapritinib is sold by Blueprint Medicines as Ayvakit for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

Promega will develop its microsatellite instability assay as a companion diagnostic for Incyte's anti-PD-1 drug candidate retifanlimab in endometrial cancer.

Data privacy firm Oasis Labs will offer a consumer-controlled data management app to customers of the DNA testing company, which was cofounded by George Church.

The tests will be developed to identify NSCLC patients with ALK fusions and EGFR Exon20 insertion mutations who respond to mobocertinib or brigatinib.

Ambry will provide RNA sequencing for Scipher's PrismRA blood test to predict response to TNF inhibitor therapies in rheumatoid arthritis patients.

An expanded agreement grants Qiagen a non-exclusive development license to Bio-Techne's exosome technology for the development of companion diagnostic products.

Covance hopes to improve and accelerate oncology clinical trial matching with the Tempus technology platform and network.

The company will work with university researchers to evaluate its predictive immune modeling technology in personalizing the use of immune checkpoint inhibitors.